Literature DB >> 20581300

Bone cancer.

J Sybil Biermann1, Douglas R Adkins, Robert S Benjamin, Brian Brigman, Warren Chow, Ernest U Conrad, Deborah A Frassica, Frank J Frassica, Suzanne George, Kenneth R Hande, Francis J Hornicek, G Douglas Letson, Joel Mayerson, Sean V McGarry, Brian McGrath, Carol D Morris, Richard J O'Donnell, R Lor Randall, Victor M Santana, Robert L Satcher, Herrick J Siegel, Neeta Somaiah, Alan W Yasko.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20581300     DOI： 10.6004/jnccn.2010.0051

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  12 in total

Review 1.  Epigenetic alterations in osteosarcoma: promising targets.

Authors:  Binghao Li; Zhaoming Ye
Journal:  Mol Biol Rep       Date:  2014-02-06       Impact factor: 2.316

2.  Usefulness of increased 18F-FDG uptake for detecting local recurrence in patients with extremity osteosarcoma treated with surgical resection and endoprosthetic replacement.

Authors:  Kyoung Jin Chang; Chang-Bae Kong; Wan Hyeong Cho; Dae-Geun Jeon; Soo-Yong Lee; Ilhan Lim; Sang Moo Lim
Journal:  Skeletal Radiol       Date:  2014-11-29       Impact factor: 2.199

3.  Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma?

Authors:  Satoshi Kawaguchi; Tao Sun; Patrick P Lin; Michael Deavers; Nusrat Harun; Valerae O Lewis
Journal:  Clin Orthop Relat Res       Date:  2013-11-07       Impact factor: 4.176

4.  Radiation therapy is associated with fewer recurrences in mesenchymal chondrosarcoma.

Authors:  Satoshi Kawaguchi; Israel Weiss; Patrick P Lin; Winston W Huh; Valerae O Lewis
Journal:  Clin Orthop Relat Res       Date:  2014-03       Impact factor: 4.176

5.  Prognostic value of IGF-1R expression in bone and soft tissue sarcomas: a meta-analysis.

Authors:  Junbo Liang; Binghao Li; Li Yuan; Zhaoming Ye
Journal:  Onco Targets Ther       Date:  2015-07-29       Impact factor: 4.147

6.  Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies.

Authors:  Vivek Subbiah; Kenneth R Hess; Muhammad Rizwan Khawaja; Michael J Wagner; Chad Tang; Aung Naing; Siqing Fu; Filip Janku; Sarina Piha-Paul; Apostolia M Tsimberidou; Cynthia E Herzog; Joseph A Ludwig; Shreyaskumar Patel; Vinod Ravi; Robert S Benjamin; Funda Meric-Bernstam; David S Hong
Journal:  Sci Rep       Date:  2016-10-17       Impact factor: 4.379

7.  C-reactive protein: An independent predictor for dedifferentiated chondrosarcoma.

Authors:  Elena Nemecek; Philipp Theodor Funovics; Gerhard Martin Hobusch; Susanna Lang; Madeleine Willegger; Florian Sevelda; Thomas Brodowicz; Christoph Stihsen; Reinhard Windhager; Joannis Panotopoulos
Journal:  J Orthop Res       Date:  2018-05-24       Impact factor: 3.494

8.  Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma.

Authors:  Binghao Li; Xiaobing Zhu; Lingling Sun; Li Yuan; Jian Zhang; Hengyuan Li; Zhaoming Ye
Journal:  Oncotarget       Date:  2014-11-15

Review 9.  T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities.

Authors:  Zhan Wang; Binghao Li; Yingqing Ren; Zhaoming Ye
Journal:  Front Immunol       Date:  2016-09-14       Impact factor: 7.561

10.  Andrographolide induces apoptosis in human osteosarcoma cells via the ROS/JNK pathway.

Authors:  Shengdong Wang; Hengyuan Li; Shi Chen; Zenan Wang; Yuhong Yao; Tao Chen; Zhaoming Ye; Peng Lin
Journal:  Int J Oncol       Date:  2020-03-30       Impact factor: 5.650
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.